[Efficacy of Ipragliflozin in Patients with Steroid-Induced Hyperglycemia during Cancer Chemotherapy].

Abstract

Steroid is a key drug in cancer chemotherapy-induced emesis. However, it may sometimes cause inadequately controlled hyperglycemia. Ipragliflozin is a novel selective sodium-dependent glucose cotransporter 2 inhibitor of urinary glucose excretion. In this case, we controlled steroid-induced hyperglycemia by administering ipragliflozin. The case was a 47-year-old man who was diagnosed with Stage IV esophageal cancer (T3N2M1). He had type 2 diabetes. He was treated with cisplatin (70 mg/m2; day 1) and 5-FU (700 mg/m2; days 1-4) as radiochemotherapy. Intravenous infusion of dexamethasone (9.9 mg) was administered on day 1, followed by additional doses (6.6 mg) for 3 days, as one of the emetic therapies. He received intensive insulin therapy during the first course of chemotherapy, but had Grade 3 hyperglycemia regardless. For the next treatment course, we additionally administered ipragliflozin along with dexamethasone. As a result, the hyperglycemia subsided to Grade 2. These findings suggest that ipragliflozin suppresses steroid-induced hyperglycemia.

• Authors: Satoshi Horasawa, Keiichiro Osame, Kenji Kawasumi, Shinichiro Saito, Hideaki Bando, Ken Ohashi
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 43 Issue 5 Pg. 645-7 (May 2016) ISSN: 0385-0684 [Print] Japan
• PMID: 27210101 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antiemetics
• Blood Glucose
• Glucosides
• Thiophenes
• ipragliflozin
• Dexamethasone

Topics

• Antiemetics (administration & dosage)
• Blood Glucose (analysis)
• Chemoradiotherapy
• Dexamethasone (adverse effects)
• Esophageal Neoplasms (pathology, therapy)
• Glucosides (therapeutic use)
• Humans
• Hyperglycemia (chemically induced, drug therapy)
• Male
• Middle Aged
• Neoplasm Staging
• Thiophenes (therapeutic use)